混合性结缔组织病:临床实践指南现状综述
本文为欧洲罕见复杂结缔组织与肌肉骨骼疾病参考网络项目下的叙述性综述,系统检索后未发现针对混合性结缔组织病(MCTD)的特异性临床实践指南,故借鉴其他结缔组织病指南讨论可应用于MCTD的内容,并提出未来指南制定的三大目标:诊断标准、初始与随访评估、治疗。
要点
- 未检索到MCTD特异性临床实践指南,现有管理参考其他结缔组织病指南。
- 未来指南应聚焦MCTD诊断标准、初始与随访评估及治疗三大目标。
- 患者未满足需求包括早期诊断、流行病学数据、疾病负担与生活质量评估。
核心结论
- 目前尚无针对MCTD的特异性临床实践指南,需借鉴其他结缔组织病指南并规划未来指南制定。
研究设计与样本
- 本文为叙述性综述,汇总了欧洲罕见复杂结缔组织与肌肉骨骼疾病参考网络项目下开展的系统性文献检索结果,旨在评估现有临床实践指南或推荐。
主要发现
- 未发现MCTD特异性临床实践指南,故考虑其他结缔组织病指南以讨论可应用于MCTD的内容。
- 提出未来MCTD指南制定的三大目标:诊断(诊断标准)、初始与随访评估、治疗。
- 患者识别的未满足需求包括早期诊断、流行病学数据、疾病负担评估及生活质量方面。
关键数值与推荐
- 未来指南制定三大目标:MCTD诊断(诊断标准)、MCTD初始和随访评估、MCTD治疗。
临床怎么用
- 临床管理MCTD时可参考其他结缔组织病指南中可迁移的内容,并关注早期诊断及生活质量评估。
局限性
- 缺乏MCTD特异性指南,综述基于其他疾病指南的借鉴讨论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mixed connective tissue disease (MCTD) is a complex overlap disease with features of different autoimmune connective tissue diseases (CTDs) namely systemic sclerosis, poly/dermatomyositis and systemic lupus erythematous in patients with antibodies targeting the U1 small nuclear ribonucleoprotein particle. In this narrative review, we summarise the results of a systematic literature research which was performed as part of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases project, aimed at evaluating existing clinical practice guidelines (CPGs) or recommendations. Since no specific CPGs on MCTD were found, other CPGs developed for other CTDs were taken into consideration in order to discuss what can be applied to MCTD even if designed for other diseases. Three major objectives were proposed for the future development of CPGs: MCTD diagnosis (diagnostic criteria), MCTD initial and follow-up evaluations, MCTD treatment. Early diagnosis, epidemiological data, assessment of burden of disease and QOL aspects are among the unmet needs identified by patients.
引用
- Chaigne B, Scirè CA, Talarico R, et al. Mixed connective tissue disease: state of the art on clinical practice guidelines. RMD Open. 2018. PMID: 30402271. doi:10.1136/rmdopen-2018-000783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。